Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade A 155.9 3.99% 5.98
BGNE closed up 3.99 percent on Thursday, February 22, 2018, on 2.96 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BGNE trend table...

Date Alert Name Type % Chg
Feb 22 New 52 Week Closing High Bullish 0.00%
Feb 22 New Uptrend Bullish 0.00%
Feb 22 Expansion Breakout Bullish Swing Setup 0.00%
Feb 22 New 52 Week High Strength 0.00%
Feb 22 Upper Bollinger Band Walk Strength 0.00%
Feb 21 MACD Bullish Signal Line Cross Bullish 3.99%
Feb 21 New 52 Week Closing High Bullish 3.99%
Feb 21 180 Bullish Setup Bullish Swing Setup 3.99%
Feb 21 Expansion Breakout Bullish Swing Setup 3.99%
Feb 21 New 52 Week High Strength 3.99%

Older signals for BGNE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 164.15
52 Week Low 34.36
Average Volume 308,240
200-Day Moving Average 81.5477
50-Day Moving Average 113.3028
20-Day Moving Average 131.46
10-Day Moving Average 133.803
Average True Range 8.196
ADX 25.79
+DI 44.96
-DI 14.81
Chandelier Exit (Long, 3 ATRs ) 139.562
Chandelier Exit (Short, 3 ATRs ) 139.048
Upper Bollinger Band 149.6194
Lower Bollinger Band 113.3006
Percent B (%b) 1.17
BandWidth 27.627263
MACD Line 8.7713
MACD Signal Line 7.0789
MACD Histogram 1.6924
Fundamentals Value
Market Cap 6.21 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -31.37
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 177.20
Resistance 3 (R3) 177.58 170.87 173.65
Resistance 2 (R2) 170.87 165.44 170.68 172.47
Resistance 1 (R1) 163.38 162.09 167.13 163.00 171.28
Pivot Point 156.67 156.67 158.54 156.48 156.67
Support 1 (S1) 149.18 151.24 152.93 148.80 140.52
Support 2 (S2) 142.47 147.89 142.28 139.33
Support 3 (S3) 134.98 142.47 138.15
Support 4 (S4) 134.60